Logo image of ABSI

ABSCI CORP (ABSI) Stock Fundamental Analysis

NASDAQ:ABSI - Nasdaq - US00091E1091 - Common Stock - Currency: USD

3.12  +0.24 (+8.33%)

After market: 3.13 +0.01 (+0.32%)

Fundamental Rating

3

Taking everything into account, ABSI scores 3 out of 10 in our fundamental rating. ABSI was compared to 558 industry peers in the Biotechnology industry. While ABSI seems to be doing ok healthwise, there are quite some concerns on its profitability. ABSI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ABSI has reported negative net income.
In the past year ABSI has reported a negative cash flow from operations.
ABSI had negative earnings in each of the past 5 years.
In the past 5 years ABSI always reported negative operating cash flow.
ABSI Yearly Net Income VS EBIT VS OCF VS FCFABSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ABSI's Return On Assets of -46.24% is in line compared to the rest of the industry. ABSI outperforms 51.79% of its industry peers.
ABSI's Return On Equity of -54.06% is fine compared to the rest of the industry. ABSI outperforms 63.08% of its industry peers.
Industry RankSector Rank
ROA -46.24%
ROE -54.06%
ROIC N/A
ROA(3y)-43.94%
ROA(5y)-42.38%
ROE(3y)-52.85%
ROE(5y)-52.12%
ROIC(3y)N/A
ROIC(5y)N/A
ABSI Yearly ROA, ROE, ROICABSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABSI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABSI Yearly Profit, Operating, Gross MarginsABSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

ABSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
ABSI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ABSI has been increased compared to 5 years ago.
The debt/assets ratio for ABSI has been reduced compared to a year ago.
ABSI Yearly Shares OutstandingABSI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ABSI Yearly Total Debt VS Total AssetsABSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 2.97 indicates that ABSI is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ABSI (2.97) is better than 73.30% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ABSI is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, ABSI is in line with its industry, outperforming 44.98% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.97
ROIC/WACCN/A
WACC9.73%
ABSI Yearly LT Debt VS Equity VS FCFABSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.72 indicates that ABSI has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.72, ABSI is in line with its industry, outperforming 59.68% of the companies in the same industry.
A Quick Ratio of 5.72 indicates that ABSI has no problem at all paying its short term obligations.
ABSI's Quick ratio of 5.72 is fine compared to the rest of the industry. ABSI outperforms 60.57% of its industry peers.
Industry RankSector Rank
Current Ratio 5.72
Quick Ratio 5.72
ABSI Yearly Current Assets VS Current LiabilitesABSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

ABSI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.96%, which is quite impressive.
ABSI shows a decrease in Revenue. In the last year, the revenue decreased by -9.93%.
The Revenue has been growing by 17.09% on average over the past years. This is quite good.
EPS 1Y (TTM)20.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.55%
Revenue 1Y (TTM)-9.93%
Revenue growth 3Y-1.75%
Revenue growth 5Y17.09%
Sales Q2Q%31.29%

3.2 Future

The Earnings Per Share is expected to grow by 10.89% on average over the next years. This is quite good.
ABSI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 62.86% yearly.
EPS Next Y9.52%
EPS Next 2Y10.76%
EPS Next 3Y11.71%
EPS Next 5Y10.89%
Revenue Next Year28.23%
Revenue Next 2Y125.34%
Revenue Next 3Y97.56%
Revenue Next 5Y62.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ABSI Yearly Revenue VS EstimatesABSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M
ABSI Yearly EPS VS EstimatesABSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABSI. In the last year negative earnings were reported.
Also next year ABSI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABSI Price Earnings VS Forward Price EarningsABSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABSI Per share dataABSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.76%
EPS Next 3Y11.71%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABSI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABSCI CORP

NASDAQ:ABSI (7/18/2025, 8:00:00 PM)

After market: 3.13 +0.01 (+0.32%)

3.12

+0.24 (+8.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners66.2%
Inst Owner Change0%
Ins Owners7.21%
Ins Owner Change1.43%
Market Cap397.99M
Analysts82.67
Price Target9.62 (208.33%)
Short Float %28.27%
Short Ratio9.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.87%
Min EPS beat(2)-2.74%
Max EPS beat(2)10.49%
EPS beat(4)1
Avg EPS beat(4)-4%
Min EPS beat(4)-13.12%
Max EPS beat(4)10.49%
EPS beat(8)1
Avg EPS beat(8)-12.76%
EPS beat(12)2
Avg EPS beat(12)-8.49%
EPS beat(16)2
Avg EPS beat(16)-23.45%
Revenue beat(2)0
Avg Revenue beat(2)-37.7%
Min Revenue beat(2)-63.32%
Max Revenue beat(2)-12.08%
Revenue beat(4)0
Avg Revenue beat(4)-28.74%
Min Revenue beat(4)-63.32%
Max Revenue beat(4)-4.87%
Revenue beat(8)1
Avg Revenue beat(8)-35.2%
Revenue beat(12)2
Avg Revenue beat(12)-34.42%
Revenue beat(16)2
Avg Revenue beat(16)-35.96%
PT rev (1m)3.33%
PT rev (3m)9.32%
EPS NQ rev (1m)3.03%
EPS NQ rev (3m)8.39%
EPS NY rev (1m)1.08%
EPS NY rev (3m)7.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.52%
Revenue NY rev (1m)-3.98%
Revenue NY rev (3m)-31.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 82.66
P/FCF N/A
P/OCF N/A
P/B 2
P/tB 2.57
EV/EBITDA N/A
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.04
BVpS1.56
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.24%
ROE -54.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.94%
ROA(5y)-42.38%
ROE(3y)-52.85%
ROE(5y)-52.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.29%
Cap/Sales 8.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.72
Quick Ratio 5.72
Altman-Z 2.97
F-Score3
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)44.41%
Cap/Depr(5y)179.67%
Cap/Sales(3y)101.78%
Cap/Sales(5y)229.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.55%
EPS Next Y9.52%
EPS Next 2Y10.76%
EPS Next 3Y11.71%
EPS Next 5Y10.89%
Revenue 1Y (TTM)-9.93%
Revenue growth 3Y-1.75%
Revenue growth 5Y17.09%
Sales Q2Q%31.29%
Revenue Next Year28.23%
Revenue Next 2Y125.34%
Revenue Next 3Y97.56%
Revenue Next 5Y62.86%
EBIT growth 1Y-19.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.01%
EBIT Next 3Y8.38%
EBIT Next 5YN/A
FCF growth 1Y14.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.9%
OCF growth 3YN/A
OCF growth 5YN/A